1 / 12

Erythropoietin

Erythropoietin. Known as EPO MW 30400Da Discovered by Miyake et al 1977from urine of anaemic pts. LC 4 alpha helical bundle class 1 cytokine 193 a.a. human (192 mouse) When levels low e.g.in CRF, chemotherapy treatment in cancer

Download Presentation

Erythropoietin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Erythropoietin • Known as EPO • MW 30400Da • Discovered by Miyake et al 1977from urine of anaemic pts. • LC 4 alpha helical bundle class 1 cytokine • 193 a.a. human (192 mouse) • When levels low e.g.in CRF, chemotherapy treatment in cancer • not effective when levels are high (high altitude, hypoxia due to CHD) • Has been used in AIDS

  2. Biological Functions • As its name suggests, EPO stimulates growth of Erythrocytes • It increases as a result of a negative feedback loop-low Oxygen=production of Epo. • Produced in the Kidneys and also in the Liver ( as Foetus: liver only) • Carries oxygen in blood

  3. Therapeutic Uses • When Epo levels low-used in aneamia resulting from chemotherapy, AIDS, CRF • Not useful if levels already high as in cases of hypoxia, high altitude living, CHD and lung disease. • Shown to improve QOL greatly in vast majority of cancer/AIDS pts

  4. RHu Epo in treatment of Anaemia of Cancer • Low levels of Epo resulting from the treatment of Cancer • treated by RHuEpo • improves Quality of life • improves anaemia in hypo-Epo cases

  5. Enables the use of Epo in therapy for CRF and cancer without unwanted immunological effects synthesised from random peptide ‘libraries’ displayed on filamentous phages ( Bacterial virus) These bind to and activate a receptor of cytokines similarly to original cytokine. 14-20 a.a. In length, serve as lead compounds for development of therapeutically effective Epo,smaller, less side effects Peptide Mimetics

  6. Epo also has therapeutic Abuses • Used in sports to improve endurance • now detected from naturally occurring EPO by protein markers appearing post-injection

  7. Erythropoietin Receptor • Hetero-dimer consisting of Beta sheets • Optimum effectiveness if 120 deg. to epo • works on JAK-stat pathway • stimulates NF-k B • protects against agoptosis

  8. Optimum Effect with 120 degree receptor angle • ‘Epo imposes a unique 120 degree angular orientation that is responsible for optimum signalling potential through intracellular kinase pathways’

  9. Stimulation of Nuclear Factor kappa B by Epo • Not JAK2 dependent • NFkB described as control switch for gene transmission (on/off). • Protects against apoptosis • new evidence for neuroprotection

  10. New Evidence for Epo in PNS • Thought to protect neural network by NF kappa B stimulation • Evidence that neuroprotective nature of Epo useful post-CVA • More evidence for neuroimmunomodulation (adds to Psychoneuroimmunological data)

  11. Epo is protective-in neural networksand during erthrocyte development May be used in treatment of stroke victims Protects against RBC apoptosis with NFkB stimulation

  12. Erythropoietin: Oxygen transport-protection- Therapeutic uses- and abuses !

More Related